Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma

Leukemia and Lymphoma

Volumn 32, Issue 1-2, 1998, Pages 139-149

  Gale, Robert Peter ^a   Park, Rolla Edward ^b   Dubois, Robert ^c   Bierman, Philip Jay ^d   Fisher, Richard I ^e   Loh, Kevin K ^f   Peterson, Bruce A ^g   Phillips, Gordon L ^h   Portlock, Carol S ⁱ   Rosenblum, Daniel ^j   Armitage, James O ^d  

^a Salick Health Care Inc   (United States)

^b RAND CORPORATION   (United States)

^c Value Health Sciences   (United States)

^d UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f QUEEN S MEDICAL CENTER   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF KENTUCKY   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j NONE

more..

Author keywords

Blood cell transplant; Bone marrow autotransplant; Delphi panel analysis; Diffuse large cell lymphoma; High dose chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD AUTOTRANSFUSION; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOTHERAPY; CLINICAL FEATURE; COMPARATIVE STUDY; DRUG MEGADOSE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RATING SCALE; RECURRENT CANCER; RETREATMENT; STATISTICAL ANALYSIS;

EID: 0032459734     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809059254     Document Type: Article

References (26)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993; 328:1023-30.
2. Goldstone AH, McMillan AK, Copra R. High-dose therapy for the treatment of non-Hodgkin's lymphoma. In: High-Dose Cancer Therapy (Armitage JO, Antman KH, ed). Baltimore, MD: Williams & Wilkins, 1995; pp 757-9.
3. Passweg JR, Rowlings PA, Armitage JO, et al. Report ,from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America. In: Clinical Transplants 1995 (Cecka JM, Teraskaki PI, ed) Los Angeles, CA: UCLA Tissue Typing Laboratory, 1996; pp 117-127.
4. Meehan KR, Pritchard RS, Leichter JW, et al. Autologous bone marrow: estimated transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma of long-term survival from the recent literature. Am J Hematol, 1995; 50:116-23.
5. Verdonck LF, Wim LJ, van Putten MSC, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med. 1995;332:1047-51.
6. Martelli M, Vignetti M, Zinzani L, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Onc. 1996;14:534-542.
7. Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. J Clin Onc. 1997; 15:1131-1137.
8. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Eng J Med. 1995; 333:1540-45.
9. Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for immediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Onc. 1994;12:2543-51.
10. Gianni A, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N-Engl J Med. 1997; 336:1290-97.
11. Brook RH, Chassin MR, Fink A, et al. A method for the detailed assessment of the appropriateness of medical technologies. Intl J Tech Assess Health Care. 1986; 2:53-63.
12. Brook RH, Chassin MR, Fink A, et al. A method for the detailed assessment of the appropriateness of medical technologies. Intl J Tech Assess Health Care. 1986; 2:53-63.
13. Park RE, Fink A, Brook RH, et al. Physician ratings of appropriate indications for six medical and surgical procedures. Am J of Publ Health. 1986;76:766-72.
14. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical use. Cancer. 1982;49:2112-35.
15. Stansfield A, Diebold J, Kapanci Y, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292-293.
16. International non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl JMed. 1993;329:987-95.
17. King SB 3rd, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emery Angioplasty versus Surgery Trial (EAST). N Engl J Med. 1994; 331:1044-50.
18. Hamm CW, Reimers J, Ischinger T, et al. A randomized study of coronary angioplasty with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med. 1994; 331:1037-43.
19. Rothwell, PM. Can overall results of clinical trials be applied to all patients? Lancet. 1995; 345:1616-9.
20. Brook RH. The RAND/UCLA appropriateness method. In: McCormick KA, Moore SR, Siegel RA, eds. Clinical practice guideline development: methodology perspectives. U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, Office of the Forum for Quality and Effectiveness in Health Care. Rockville, MD; Pub. No. 95-0009, 1994; p.59-70.;
21. also available as Brook RH. The RAND/UCLA appropriateness method: Rand/RP-395. Santa Monica, CA: Rand Corporation: 1994;59-70.
22. Shekelle PG, Chassin MR, Park RE. Evidence for the validity of criteriafor performing carotoid endarterectomy. Int J Tech Assessment in Health Care (in press).
23. Merrick NJ, Fink A, Park RE, et al. Derivation of clinical indications for carotid endarterectomy by an expert panel. AM J Pub Health. 1987;77:187-90.
24. Shekelle PG, Chassin MR, Park RE. Evidence for the validity of criteria for performing carotoid endarterectomy. N Engl J Med (in press).
25. Selby JVB, Fireman BH, Lundstrom RJ, et al. Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization. N Eng J Med. 1996; 335: 1888-96.
26. Kravitz, RL, Laouri M, Kahan JP, et al. Validity of criteria used for detecting underuse of coronary revascularization. JAMA. 1995;274:632-8.